Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Medical supply

- PMLiVE

Brexit deal defeated again, crucial no-deal vote awaits

UK pharma urges no-deal to be ruled out

- PMLiVE

Shionogi planning HQ move from UK

Brexit understood to be main reason for switch

“Brexit has been a catalyst for UK clinical research… it’s turbocharged change”

The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?

- PMLiVE

Tecentriq combo gains European NSCLC approval

Triple combination approved after targeted therapy

- PMLiVE

Trump’s Brexit trade plan is bad for NHS, say campaigners

People’s Vote claims US wants to end NHS’ current regime of controlling drug costs

- PMLiVE

AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

Analysts say the drug could be a best-in-class candidate in the therapy area

- PMLiVE

UCB looks to pipeline with five years left for twin blockbusters

CEO outlines pipeline promise, won't write off post-Brexit UK

- PMLiVE

Pharma industry swamped with no-deal Brexit info, says BIA

Deluge comes just as prime minister hints at delay

- PMLiVE

As government rushes through no-deal legislation, UK biotech repeats Brexit plea

UK market would be relegated in importance

- PMLiVE

Industry aghast as EU Parliament backs biosimilar rule change

The change could come into effect in 2021

- PMLiVE

Industry concerned about ‘rushed’ Brexit withdrawal legislation

The Patents Amendment could weaken the UK’s IP framework, warns biopharma

- PMLiVE

No deal Brexit would see UK miss out on ‘safest medicines system in the world’

Health leaders say it would be 'a travesty'

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links